Clinical trials: Metastatic Clear Cell Renal Cell Carcinoma
Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).
- Conditions
- Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Kidney Neoplasms
- Trial name
- NCT02837991
- Testing
- CDX-014
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celldex Therapeutics
Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
CLEAR CAR-T cell injection (ET-970) is an engineered CD70-targeting allogeneic Chimeric Antigen Receptor T-Cell (CAR-T cell). This is a multi-center, single-arm, open-label, early exploratory clinical study.
- Trial name
- NCT07645690
- Testing
- CLEAR CAR-T cell injection
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Renal Cell Carcinoma Metastatic
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.
- Trial name
- NCT06321250
- Testing
- JMKX003948
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jemincare
Clear Cell Metastatic Renal Cell Carcinoma
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
Stereotactic radiotherapy (SRT) is a newer type of focused radiation therapy that precisely and accurately delivers high dose radiation to a tumour, while sparing much of the nearby normal organs.
- Trial name
- NCT02019576
- Testing
- Stereotactic radiotherapy
- Where
- 12 sites in Canada
- Volunteers
- 38 people
- Sponsor
- Sunnybrook Health Sciences Centre
Melanoma, Kidney Neoplasms
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of…
- Conditions
- Melanoma, Kidney Neoplasms, Metastases
- Trial name
- NCT00095108
- Testing
- Recombinant Human Interleukin-21
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- ZymoGenetics
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01158222
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Case Comprehensive Cancer Center
Renal Cell Carcinoma
A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
Study MO39939 is an open-label, single-arm, multicenter trial in patients with unresectable, locally-advanced or metastatic, clear or non-clear cell renal cell carcinoma (RCC) who have not received prior systemic therapy (who are…
- Trial name
- NCT03693573
- Testing
- Atezolizumab, Bevacizumab
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
- Trial name
- NCT04883827
- Testing
- Blood collection, Urine collection
- Where
- 3 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Renal Cell Carcinoma Metastatic
Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
The trial studies the effects of personalized home-based aerobic and resistance exercises on quality of life, changes in physical activity levels, and the change in inflammatory myokines with the exercise intervention in…
- Trial name
- NCT05103722
- Testing
- Combined Aerobic and Resistance Exercise Training
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Kidney Cancer
High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill renal cell carcinoma (kidney cancer) cells. PURPOSE: This phase II trial is studying how well high-dose intravenous interleukin-2 works in treating…
- Trial name
- NCT00080977
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Blumenthal Cancer Center at Carolinas Medical Center
Kidney Cancer
Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
The goal of this clinical research study is learn if carfilzomib can help control kidney cancer. The safety of this drug will also be studied. Carfilzomib is designed to block cancer cells from repairing themselves.
- Trial name
- NCT01775930
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received…
- Trial name
- COMPARZ (NCT00720941)
- Testing
- Pazopanib, Sunitinib
- Where
- 227 sites in United States, Australia and 12 more
- Volunteers
- 1,110 people
- Sponsor
- Novartis Pharmaceuticals
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Advanced Malignancies, Metastatic Cancer
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts.
- Trial name
- NCT02697591
- Testing
- INCAGN01876
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Incyte Biosciences International Sàrl
Metastatic Renal Cancer
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Summary Renal Cell Carcinoma (RCC) consists of 2% of all malignencies. RCCs are generally divided to histopathological subtypes as clear cell and non-clear cell variants. Clear cell variant responsible for the 75-80% of all RCCs.
- Trial name
- NCT06959433
- Testing
- Lu-177 PSMA-617
- Volunteers
- 20 people
- Sponsor
- Ankara University
Metastatic Clear Cell Renal Cell Carcinoma
Imaging Study in Metastatic Clear Cell RCC.
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).
- Trial name
- NCT07671417
- Testing
- RYZ512
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 10 people
- Sponsor
- RayzeBio, Inc.
Renal Cell Carcinoma
RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma
The purpose of this study is to look at the effects of a procedure called radiofrequency ablation on kidney tumors from patients who are undergoing antiangiogenic treatment.
- Trial name
- NCT00601120
- Testing
- Radiofrequency Ablation
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
This phase II trial tests how well zanzalintinib and MO-03 works for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing…
- Trial name
- NCT07578025
- Testing
- Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- City of Hope Medical Center
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
This phase II trial is studying how well giving sorafenib with interferon alfa works in treating patients with metastatic or unresectable kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00101114
- Testing
- sorafenib tosylate, recombinant interferon alfa-2b, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Lymphocyte Therapy in Treating Patients With Kidney Cancer
RATIONALE: Treating a person's lymphocytes with interleukin-2 and monoclonal antibody may help them kill more cancer cells when they are put back in the body.
- Trial name
- NCT00002589
- Testing
- aldesleukin, muromonab-CD3, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)